Deutsche Bank AG decreased its holdings in Cascadian Therapeutics Inc (NASDAQ:CASC) by 75.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 81,083 shares of the biopharmaceutical company’s stock after selling 244,491 shares during the quarter. Deutsche Bank AG owned 0.16% of Cascadian Therapeutics worth $299,000 as of its most recent SEC filing.
Other institutional investors have also bought and sold shares of the company. SG Americas Securities LLC grew its position in Cascadian Therapeutics by 194.7% in the fourth quarter. SG Americas Securities LLC now owns 38,541 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 25,464 shares during the last quarter. Alps Advisors Inc. acquired a new position in Cascadian Therapeutics in the fourth quarter worth approximately $207,000. Renaissance Technologies LLC grew its position in Cascadian Therapeutics by 28.1% in the fourth quarter. Renaissance Technologies LLC now owns 81,688 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 17,900 shares during the last quarter. Unterberg Capital LLC acquired a new position in Cascadian Therapeutics in the fourth quarter worth approximately $370,000. Finally, Essex Investment Management Co. LLC acquired a new position in Cascadian Therapeutics in the fourth quarter worth approximately $567,000. Hedge funds and other institutional investors own 81.38% of the company’s stock.
NASDAQ CASC opened at $10.02 on Friday. Cascadian Therapeutics Inc has a twelve month low of $3.18 and a twelve month high of $10.21.
Several research analysts have issued reports on CASC shares. Cantor Fitzgerald set a $10.00 price target on shares of Cascadian Therapeutics and gave the stock a “hold” rating in a research report on Friday, March 9th. Raymond James cut shares of Cascadian Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 31st. BidaskClub cut shares of Cascadian Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, March 7th. Finally, ValuEngine upgraded shares of Cascadian Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 31st. Three analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $6.17.
Cascadian Therapeutics Company Profile
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.